Half of patients stop GLP-1s within a year
In some studies, half or more of people stop taking GLP-1 medications within a year of starting, limiting their long-term effectiveness.
Snapshot · TED Talks Daily
Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech
Explore episode
Jun 26, 2026
Where this was said
The Many Conditions GLP-1s May Treat Beyond Addiction
At 32:12 · chapter starts 31:50
Manoush asks about off-label GLP-1 use, and Khullar opens up the full breadth of emerging evidence. Beyond diabetes and obesity, studies are showing benefits for cardiovascular risk, stroke, fatty liver disease, chronic kidney disease, and even osteoarthritis [1] — Dhruv Khullar "GLP-1 affects fatty liver, kidney disease: Studies show GLP-1 medications can slow or even reverse fatty liver disease and chronic kidney d…" 31:32 . Some effects appear independent of weight loss entirely, pointing toward an anti-inflammatory mechanism. Khullar is careful to note he approached these claims with skepticism — and was surprised to find the evidence repeatedly holding up. He frames this as a genuinely novel drug class, not just another obesity pill, while warning that evidence is still catching up to real-world usage patterns.
The Downsides of GLP-1s: Cost, Dropout, and Muscle Loss
More than half of patients stop GLP-1 medications within a year, whether from side effects, cost, or access. The sticker price can hit $1,300 a month. The drugs also cause muscle loss alongside fat loss, raising frailty concerns — which is why high-protein diets and strength training are essential companions. These are not simple, affordable, or side-effect-free drugs.
GLP-1 sticker price up to $1,300/month
The sticker price for GLP-1 medications can reach $1,000–$1,300 per month, making them inaccessible for many patients.
First GLP-1 drug launched in 2005–2006
The first GLP-1 medication (exenatide) was approved around 2005–2006, meaning these drugs have a roughly 20-year safety track record, providing some reassurance about long-term effects.
Similar snapshots
50% of U.S. adults report being lonely
The U.S. Surgeon General's 2023 report on loneliness found that half of American adults report feeling lonely, marking a widespread epidemic of social isolation.
Brain.fm increased focus brainwave activity by 119%
In a peer-reviewed study, Brain.fm's audio technology was shown to increase focus-related brainwave activity by 119%, according to the show's sponsor read.
Wealthier countries have highest rates of anxiety and depression
The Easterlin Paradox shows that wealthier nations — and the wealthiest neighborhoods within them — tend to have the highest rates of anxiety, depression, loneliness, and suicide.
More than 3 in 4 Americans report anxiety or depression
Mental health challenges are nearly universal — BetterHelp's own research found the majority of Americans experiencing symptoms right now.
Medicaid 5-year look-back rule
When applying for Medicaid to cover nursing home costs, there is a 5-year look-back period that can disqualify applicants who gave away or spent down assets.
Pipe broke → hydrogen sulfide studio air
A broken pipe filled the Bad Friends studio with what the hosts identified as hydrogen sulfide — microscopic fecal aeroparticles — that the crew denied smelling.
Robot surgery: 10x less blood loss
Fei-Fei Li's father's liver surgery performed by a da Vinci robot resulted in 10 times less blood loss than a typical open liver surgery, thanks to laparoscopic precision.
115M US adults have prediabetes
Approximately 115 million adults in the US currently have prediabetes, most of whom are unaware, according to the Lingo sponsor segment.
Drug overdose deaths: 110K to 80K to 70K
Drug overdose deaths in the US fell from 110,000 to 80,000 in 2024, and then to roughly 70,000 — the largest single-year drop the CDC has ever recorded.
